A study has shown that tissue-resident CD69+ CXCR6+ NK cells with depletion phenotype accumulate in human non-small cell lung cancer and are a promising target for immune checkpoint inhibitors in the treatment of NSCLC (25). This evidence concerns the gene CD69 and non-small cell lung carcinoma.